Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03485651 · ClinicalTrials.gov registry record
Natera Ovarian Cancer Detection Assay
A clinical trial, sponsored by Natera.
- Terminated
- Registry status
- 12
- Enrollment target
NCT03485651: Clinical Trial study, sponsored by Natera.
NCT03485651 is a clinical trial that was terminated before completion, run by Natera. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03485651 was terminated before completion, sponsored by Natera.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to enroll participants who present with an adnexal mass on imaging to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses. The study will collect blood, tissue, and health information from these individuals.
Primary Outcome
Examine ctDNA between benign ovarian masses and confirmed ovarian cancer cases (based on tumor pathology report). The purpose of this outcome is to determine whether cfDNA could be used to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-12-14 |
| Est. Completion | 2019-12-31 |
Why NCT03485651 stopped before completion
NCT03485651 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03485651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03485651 about?
NCT03485651 is a clinical study titled "Natera Ovarian Cancer Detection Assay". The purpose of this study is to enroll participants who present with an adnexal mass on imaging to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses. The study will collect blood, tissue, and health information from these individuals.
What is the current status of trial NCT03485651?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2017-12-14. Estimated completion is 2019-12-31.
Who is sponsoring clinical trial NCT03485651?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI